Data Confirm Dasatinib's Effectiveness in Resistant Chronic Myelogenous Leukemia, Dana-Farber Cancer Institute Study

Updated clinical trial results show that the drug dasatinib (Sprycel) continues to be highly effective in patients with chronic myelogenous leukemia who were unable to tolerate Gleevec or who developed resistance to it, reports a team led by researchers at Dana-Farber Cancer Institute. Richard Stone, MD, of Dana-Farber, will present the results of the START-C trial at the annual meeting of the American Society of Hematology on Tuesday, Dec. 11, in Atlanta.